russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2023-5457russjcardiol-5457Research ArticleОБЗОРЫREVIEWОбзор результатов ASCOT Legacy 20 летReview of 20-year results of ASCOT Legacyhttps://orcid.org/0000-0002-5542-0948НагорныйМ. Б.NagornyM. B.

Кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней

Санкт-Петербург

St. Petersburg

ilikedm@mail.ruhttps://orcid.org/0000-0003-2888-9625КучминА. Н.KuchminA. N.

Доктор медицинских наук, зав. кафедрой пропедевтики внутренних болезней, профессор, Заслуженный врач Российской Федерации

Санкт-Петербург

St. Petersburg

ФГБВОУ ВО Военно-медицинская академия им. С. М. Кирова Министерства обороны Российской ФедерацииРоссияS. M. Kirov Military Medical AcademyRussian Federation20231005202328554575457Copyright © Нагорный М.Б., Кучмин А.Н., 20232023Нагорный М.Б., Кучмин А.Н.Nagorny M.B., Kuchmin A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/5457

В статье представлены результаты 20-летнего наблюдения за пациентами в рамках исследования ASCOT Legacy, свидетельствующие о том, что применение антигипертензивной и липидснижающей терапии уменьшает смертность пациентов с артериальной гипертензией и высоким сердечно-сосудистым рис­ком в долгосрочной перспективе. В группе пациентов, получавших лечение на основе амлодипина по сравнению с лечением на основе β-блокатора атенолола, отмечено снижение среднего систолического артериального давления (АД) и диастолического АД, наблюдался долгосрочный положительный эффект в виде снижения частоты сердечно-сосудистых событий и смертности от инсульта. Важной особенностью терапии на основе амлодипина стало снижение вариабельности АД. В статье отражены результаты крупных исследований, определяющих возможность и эффективность раннего назначения комбинированной антигипертензивной и липидснижающей терапии.

The article presents the results of a 20-year follow-up of patients in the ASCOT Legacy study, indicating that antihypertensive and lipid-lowering therapy reduces mortality in patients with hypertension and high cardiovascular risk in the long term. In the group of patients treated with amlodipine compared with the β-blocker atenolol, there was a decrease in mean systolic and diastolic blood pressure (BP), as well as a long-term improve in the form of a decrease in the prevalence of cardiovascular events and mortality due to stroke. An important feature of therapy based on amlodipine was the reduction in BP variability. The article reflects the results of major studies that determine the possibility and effectiveness of early prescription of combined antihypertensive and lipid-lowering therapy.

амлодипинартериальная гипертензияартериальное давлениевариабельность артериального давлениясердечно-сосудистый рискпериндоприлфиксированные комбинацииamlodipinehypertensionblood pressureblood pressure variabilitycardiovascular riskperindoprilfixed-dose combinationsReferencesWorld Health Organization. Global Health Estimates 2015: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2015. Evidence and Research (2016).World Health Organization. Global Health Estimates 2015: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2015. Evidence and Research (2016).NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80. doi:10.1016/S0140-6736(21)01330-1.NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80. doi:10.1016/S0140-6736(21)01330-1.Teo KK, Rafiq T. Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries. Canadian Journal of Cardiology. 2021;37(5):733-43. doi:10.1016/j.cjca.2021.02.0094.Teo KK, Rafiq T. Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries. Canadian Journal of Cardiology. 2021;37(5):733-43. doi:10.1016/j.cjca.2021.02.0094.Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an anti¬hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. doi:10.1016/S0140-6736(05)67185-1.Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an anti¬hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. doi:10.1016/S0140-6736(05)67185-1.Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomized factorial trial. Lancet. 2018;392(10153):1127-37. doi:10.1016/S0140-6736(18)31776-8.Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomized factorial trial. Lancet. 2018;392(10153):1127-37. doi:10.1016/S0140-6736(18)31776-8.Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005;165(10):1147-52. doi:10.1001/archinte.165.10.1147.Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihyper¬tensive and lipid-lowering therapy. Arch. Intern. Med. 2005;165(10):1147-52. doi:10.1001/archinte.165.10.1147.ASCOT Legacy: Long-Term Benefits of BP, Cholesterol Management on HTN Aug 26, 2018 ACC News Story. https://www.acc.org/latest-in-cardiology/articles/2018/08/20/17/59/sun-5am-ascot-esc-2018.ASCOT Legacy: Long-Term Benefits of BP, Cholesterol Management on HTN Aug 26, 2018 ACC News Story. https://www.acc.org/latest-in-cardiology/articles/2018/08/20/17/59/sun-5am-ascot-esc-2018.Sever P, Gupta A, Whiteley W, et al. S-28-8: The ASCOT LEGACY cohort: the long-term effects of blood pressure and blood pressure variability on cardiovascular and renal outcomes. Journal of Hypertension. 2023;41,e-Supplement 1,e67-e68. doi:10.1097/01.hjh.0000913376.59859.51.Sever P, Gupta A, Whiteley W, et al. S-28-8: The ASCOT LEGACY cohort: the long-term effects of blood pressure and blood pressure variability on cardiovascular and renal outcomes. Journal of Hypertension. 2023;41,e-Supplement 1,e67-e68. doi:10.1097/01.hjh.0000913376.59859.51.Gupta A, Whiteley W, Godec T, et al. The relationship between BP-control, BP-variability and antihypertensive treatment with the longterm risk of cardiovascular event: lessons from the ASCOT-LEGACY 20-year follow-up, Journal of Hypertension. 2021;39:e148. doi:10.1097/01.hjh.0000745996.70900.76.Gupta A, Whiteley W, Godec T, et al. The relationship between BP-control, BP-variability and antihypertensive treatment with the longterm risk of cardiovascular event: lessons from the ASCOT-LEGACY 20-year follow-up, Journal of Hypertension. 2021;39:e148. doi:10.1097/01.hjh.0000745996.70900.76.Gupta A, Whiteley W, Godec T, et al. Long term benefits of blood pressure treatment on the incidence of atrial fibrillation, heart failure and cardiovascular morbidity and mortality: 20-years follow-up of ASCOT-LEGACY. Journal of Hypertension. 2021;39:e8. doi:10.1097/01.hjh.0000744436.51700.9f42.Gupta A, Whiteley W, Godec T, et al. Long term benefits of blood pressure treatment on the incidence of atrial fibrillation, heart failure and cardiovascular morbidity and mortality: 20-years follow-up of ASCOT-LEGACY. Journal of Hypertension. 2021;39:e8. doi:10.1097/01.hjh.0000744436.51700.9f42.Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25. doi:10.1161/CIRCULATIONAHA.105.595496.Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25. doi:10.1161/CIRCULATIONAHA.105.595496.Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension. 2018;7(4):846-53. doi:10.1161/HYPERTENSIONAHA.118.11308.Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension. 2018;7(4):846-53. doi:10.1161/HYPERTENSIONAHA.118.11308.Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-57. doi:10.1161/HYPERTENSIONAHA.120.15026.Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-57. doi:10.1161/HYPERTENSIONAHA.120.15026.Bangalore S, Kumar S, Messerli FH, et al. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians’ Desk Reference. Am. J. Med. 2010;123(11):1016-30. doi:10.1016/j.amjmed.2010.06.014.Bangalore S, Kumar S, Messerli FH, et al. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians’ Desk Reference. Am. J. Med. 2010;123(11):1016-30. doi:10.1016/j.amjmed.2010.06.014.Arnold JM, Yusuf S, Young J, et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107(9):1284-90. doi:10.1161/01.cir.0000054165.93055.42.Arnold JM, Yusuf S, Young J, et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107(9):1284-90. doi:10.1161/01.cir.0000054165.93055.42.Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc. Res. 2007;73(1):237-46. doi:10.1016/j.cardiores.2006.10.021.Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc. Res. 2007;73(1):237-46. doi:10.1016/j.cardiores.2006.10.021.PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41. doi:10.1016/S0140-6736(01)06178-5.PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41. doi:10.1016/S0140-6736(01)06178-5.Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217-25. doi:10.1001/jama.292.18.2217.Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217-25. doi:10.1001/jama.292.18.2217.Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 2004;351(20):2058-68. doi:10.1056/NEJMoa042739.Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 2004;351(20):2058-68. doi:10.1056/NEJMoa042739.Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008;358(15):1547-59. doi:10.1056/NEJMoa0801317.Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008;358(15):1547-59. doi:10.1056/NEJMoa0801317.Wei J, Galaviz KI, Kowalski AJ, et al. Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis. JAMA Netw. Open. 2020;3(2):e1921618. doi:10.1001/jamanetworkopen.2019.21618.Wei J, Galaviz KI, Kowalski AJ, et al. Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis. JAMA Netw. Open. 2020;3(2):e1921618. doi:10.1001/jamanetworkopen.2019.21618.Kim YH, Her A-Y, Jeong MH, et al. Comparison of clinical outcomes between angio¬-tensin-converting-enzyme inhibitors and ARBs in patients with acute myocardial infarction with dyslipidemia after a successful stent implantation. Anatol. J. Cardiol. 2020;23(2):86-98. doi:10.14744/AnatolJCardiol.2019.60374.Kim YH, Her A-Y, Jeong MH, et al. Comparison of clinical outcomes between angio¬-tensin-converting-enzyme inhibitors and ARBs in patients with acute myocardial infarction with dyslipidemia after a successful stent implantation. Anatol. J. Cardiol. 2020;23(2):86-98. doi:10.14744/AnatolJCardiol.2019.60374.Карпов Ю. А., Деев А. Д. Неконтролируемая артериальная гипертония — новые возможности в решении проблемы повышения эффективности лечения. Кардиология. 2012;2:29-35.Karpov YuA, Deev AD. Uncontrolled arterial hypertension — new opportunities in solving the problem of improving the effectiveness of treatment. Kardiologiia. 2012;2:29-35. (In Russ.)Карпов Ю. А., Сорокин Е. В. Влияние комбинированной гипотензивной терапии на риск сердечно-сосудистых осложнений и сосудистый возраст: результаты многоцентрового открытого исследования ADVANT’AGE. Атмосфера. Новости кардиологии. 2015;3:2-10.Karpov YuA, Sorokin EV. The effect of combined hypotensive therapy on the risk of car¬diovascular complications and vascular age: the results of a multicenter open study of ADVANTAGE’AGE. Atmosphere. Cardiology news. 2015;3:2-10. (In Russ.)Недогода С. В., Конради А. О., Звартау Н. Э. и др. Оптимизация контроля артериального давления и ангиопротекции с помощью фиксированной комбинации периндоприла и амлодипина у пациентов с артериальной гипертензией и высокой скоростью распространения пульсовой волны. Кардиология. 2017;57(3):31-8.Nedogoda SV, Konradi AO, Zvartau NE, et al. Optimization of blood pressure control and angioprotection using a fixed combination of perindopril and amlodipine in patients with arterial hypertension and high pulse wave propagation velocity. Kardiologiia. 2017;57(3):31-8. (In Russ.)Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133-46. doi:10.1016/S0140-6736(21)01827-4.Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133-46. doi:10.1016/S0140-6736(21)01827-4.Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am. J. Med. 2012;125(9):882-7. doi:10.1016/j.amjmed.2011.12.013.Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am. J. Med. 2012;125(9):882-7. doi:10.1016/j.amjmed.2011.12.013.Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur. Heart J. 2013;34(38):2940-8. doi:10.1093/eurheartj/eht295.Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur. Heart J. 2013;34(38):2940-8. doi:10.1093/eurheartj/eht295.Российское кардиологическое общество (РКО). Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. doi:10.15829/29/1560-4071-2020-4076.Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi:10.15829/29/1560-4071-2020-4076.Jacob S, Weger B. Blood pressure, lipid lowering and self-reported adherence with a fixed-dose combinaton of Atorvastatin/Perindopril/Amlodipine in primary care: a non-interventional study. Der Internist. 2018;59(1):PS157. doi:10.1097/01.HJH.0000523313.46927.8F.Jacob S, Weger B. Blood pressure, lipid lowering and self-reported adherence with a fixed-dose combinaton of Atorvastatin/Perindopril/Amlodipine in primary care: a non-interventional study. Der Internist. 2018;59(1):PS157. doi:10.1097/01.HJH.0000523313.46927.8F.Simon A, Dezsi CA. Treatment of hypertensive and hypercholesterolaemic patients with the triple fixed combination of atorvastatin, perindopril and amlodipine: the results of the CORAL study. Adv. Ther. 2019;36(8):2010-20. doi:10.1007/s12325-019-01002-8.Simon A, Dezsi CA. Treatment of hypertensive and hypercholesterolaemic patients with the triple fixed combination of atorvastatin, perindopril and amlodipine: the results of the CORAL study. Adv. Ther. 2019;36(8):2010-20. doi:10.1007/s12325-019-01002-8.Dezsi СА. Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: a subgroup analysis from the PAPA-CAD study. J. Int. Med. Res. 2018;46(5):1902-9. doi:10.1177/0300060518760158.Dezsi СА. Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: a subgroup analysis from the PAPA-CAD study. J. Int. Med. Res. 2018;46(5):1902-9. doi:10.1177/0300060518760158.

The authors declare that there are no conflicts of interest present.